- Home
- AMAL vs ANAB Comparison
AMAL vs ANAB Comparison
Compare AMAL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ANAB |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AMAL | ANAB |
|---|---|---|
| Price | $50.58 | $48.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $56.00 | ★ $87.25 |
| AVG Volume (30 Days) | 195.4K | ★ 404.9K |
| Earning Date | 10-22-2026 | 11-20-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 3.19 | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $15.29 | N/A |
| Revenue Next Year | $5.69 | $69.42 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $26.61 | $32.20 |
| 52 Week High | $52.30 | $73.30 |
Technical Indicators
Market Signals| Indicator | AMAL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 57.16 | 48.20 |
| Support Level | $45.40 | $44.25 |
| Resistance Level | $51.25 | $51.70 |
| Average True Range (ATR) | 1.30 | 1.90 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 63.12 | 46.70 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).